Phase I study of the cytotoxic agent N-[2-(dimethylamino) ethyl]acridine-4-carboxamide

Cancer Chemotherapy and Pharmacology

Volumn 44, Issue 1, 1999, Pages 39-44

  McCrystal, Michael R ^a   Evans, Barrie D ^a   Harvey, Vernon J ^a   Thompson, Paul I ^a   Porter, David J ^a   Baguley, Bruce C ^b  

^a AUCKLAND CITY HOSPITAL   (New Zealand)

^b UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

DACA; Phase I; Topoisomerase

Indexed keywords

CYTOTOXIC AGENT; DNA TOPOISOMERASE; N (2 DIMETHYLAMINOETHYL) 4 ACRIDINECARBOXAMIDE;

ADULT; AGED; ANTINEOPLASTIC ACTIVITY; AREA UNDER THE CURVE; ARTICLE; CANCER; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE CALCULATION; DRUG CYTOTOXICITY; DRUG MECHANISM; DRUG SCREENING; FEMALE; HUMAN; INJECTION PAIN; INTRAVENOUS DRUG ADMINISTRATION; MALE; NAUSEA; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; THROMBOPHLEBITIS;

ACRIDINES; ADULT; AGED; ANTINEOPLASTIC AGENTS; DOSE-RESPONSE RELATIONSHIP, DRUG; FACIAL PAIN; FEMALE; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; NEOPLASMS;

EID: 0032991591     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s002800050942     Document Type: Article

References (13)

1. Baguley BC, Zhuang L, Marshall E (1995) Experimental solid tumour activity of N-[2-(dimethylamino)ethyl]-acridine-4-carboxamide. Cancer Chemother Pharmacol 36: 244-248
2. Coatsworth JK (1993) Report 1243/1. A multiple dose toxicity study in the mouse and rat by the intravenous route. Bibra Toxicology International, Carshalton, UK
3. Cornford EM, Young D, Paxton JW (1992) Comparison of the blood-brain barrier and liver penetration of acridine antitumor drugs. Cancer Chemother Pharmacol 29: 439-444
4. EORTC Pharmacokinetics and Metabolism Group (1987) Pharmacokinetically guided dose escalation in phase I clinical trials. Commentary and proposed guidelines. Eur J Cancer Clin Oncol 23: 1083-1087
5. Evans SMH, Robertson IGC, Paxton JW (1994) Plasma protein binding of the experimental antitumour agent acridine-4-carboxamide in man, dog, rat and rabbit. J Pharm Pharmacol 46: 63-67
6. Evans SMH, Young D, Robertson IGC, Paxton JW (1992) Intraperitoneal administration of the antitumour agent N-[(2-(dimethylamino)ethyl)]acridine-4-carboxamide in the mouse: bioavailability, pharmacokinetics and toxicity after a single dose. Cancer Chemother Pharmacol 31: 32-36
7. Finlay GJ, Marshall ES, Matthews JHL, Paull KD, Baguley BC (1993) In vitro assessment of N-[2-(dimethylamino)ethyl]acridine-4-carboxamide, a DNA-intercalating antitumour drug with reduced sensitivity to multidrug resistance. Cancer Chemother Pharmacol 31: 401-406
8. Finlay GJ, Riou J-F, Baguley BC (1996) From amsacrine to DACA (N-[2-(dimethylamino)ethyl]acridine 4-carboxamide): selectivity for topoisomerases I and II among acridine derivatives. Eur J Cancer 32 A: 708-714
9. Kestell P, Dunlop I, McCrystal MR, Evans BD, Paxton JW, Gamage RSKA, Baguley BC (1999) Plasma pharmacokinetics of N-[2-(dimethylamino)-ethyl]-acridine-4-carboxamide (DACA) in a phase I trial. Cancer Chemother Pharmacol (in press)
10. Paxton JW, Young D, Evans SM, Kestell P, Robertson IG, Cornford EM (1992) Pharmacokinetics and toxicity of the antitumour agent N-[2-(dimethylamino)ethyl]acridine-4-carboxamide after i.v. administration in the mouse. Cancer Chemother Pharmacol 29: 379-384
11. Schofield PC, Robertson IGC, Paxton JW, Gamage RSKA, McCrystal MR, Evans BD, Kestell P, Baguley BC (1999) Metabolism of N-[2'-(dimethylamino)ethyl]acridine-4-carboxamide (DACA) in cancer patients undergoing a phase I clinical trial. Cancer Chemother Pharmacol (in press)
12. World Health Organisation (1979) Handbook for reporting results of cancer treatment. World Health Organisation, Geneva
13. Bono JS de, et al (1998) A phase I study of XR5000 (DACA) by 120 hour intravenous infusion. Proceedings, 10th NCI-EORTC symposium on new drugs in cancer therapy, Amsterdam, June 16-18